US stock insider trading | Olema disclosed 5 insider transactions on March 5

K-LinePoet · 2026-04-09T12:47:48+00:00

On March 5, 2026, Olema announced multiple insider transactions by executive Mitchell Shawnte, including the purchase of 40k shares on March 4, as well as the sale of 24.8k shares and 233 shares. Recently, other executives and directors have also made several transactions. Olema is a biopharmaceutical company focused on treatments for women's cancers.

K-LinePoet

2026-04-09 12:47:48

Abstract generation in progress

On March 5, 2026, Olema (OLMA) disclosed five insider trading transactions. Executive Mitchell Shawnte bought 25k shares on March 4, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 5, 2026	Executive	Mitchell Shawnte	March 4, 2026	Sell	233	24.69	5,752.77
March 5, 2026	Executive	Mitchell Shawnte	March 3, 2026	Sell	15k	23.01	345.2k.00
March 5, 2026	Executive	Mitchell Shawnte	March 4, 2026	Sell	24.8k	24.25	602,600.00
March 5, 2026	Executive	Mitchell Shawnte	March 4, 2026	Buy	40k	4.37	174.8k.00
January 21, 2026	Director	Harmon Cyrus	January 20, 2026	Sell	10k	26.88	268.8k.00
January 16, 2026	Director	Harmon Cyrus	January 14, 2026	Sell	3,489	29.12	101,416.80
January 15, 2026	Executive	Kovacs Shane William Charles	January 13, 2026	Sell	3,822	28.01	107,124.22
January 15, 2026	Executive	Kovacs Shane William Charles	January 15, 2026	Sell	100k	28.73	2.87M.00
January 14, 2026	Executive	Myles David C.	January 14, 2026	Sell	35k	28.99	1,014,650.00
January 14, 2026	Executive	Myles David C.	January 14, 2026	Sell	15k	28.60	429,000.00

[Company Profile]

Olema Pharmaceuticals, Inc., located in San Francisco, California, was incorporated on August 7, 2006, in Delaware. The company is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing next-generation targeted therapies for women’s cancers.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.